ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1616826
This article is part of the Research TopicAdvances in the Potential Treatments of Gastrointestinal and Liver Diseases: Addressing the Public Health Burden, Volume IIView all 5 articles
Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis
Provisionally accepted
- 1Shanghai Cancer Center, Fudan University, Shanghai, China
- 2Xuzhou Medical University, Xuzhou, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The ARMANI trial demonstrated that ramucirumab plus paclitaxel (switch maintenance group) significantly prolonged progression-free survival (PFS) and overall survival in patients with advanced HER2-negative gastric cancer (GC) and gastroesophageal junction cancer (GEJC) compared to continued first-line oxaliplatin-based chemotherapy (control group). However, its cost-effectiveness remained unclear. This study aimed to evaluate its cost-effectiveness from the Chinese and United State (US) healthcare system perspective.Methods: A partitioned survival model was developed to compare the total costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) of switch maintenance group versus control group over a 10-year time horizon.Survival data were sourced from the ARMANI trial. Cost and utility were derived from open-access databases and published literature. The robustness of the results was verified through one-way sensitivity analysis and probabilistic sensitivity analysis (PSA). Additionally, subgroup analysis and scenario analysis were conducted.The switch maintenance group yielded incremental gains of 0.15 QALYs in China and 0.
Keywords: Ramucirumab, Paclitaxel, gastric cancer, Gastro-oesophageal junction cancer, Cost-Effectiveness
Received: 23 Apr 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Luo, Li, Du and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jiefeng Luo, Shanghai Cancer Center, Fudan University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.